About this Research Topic
The clinical approval of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy has demonstrated considerable success in treating hematologic malignancies. Although CAR T cells have shown promising outcomes in clinical trials, they cause serious side effects such as CRS, GVHD, and neural toxicity which limits their clinical application in a broad range of cancers. Multiple myeloma is a bone marrow cancer, caused by the abnormal proliferation of plasma cells. Over the past decades, several novel agents were developed to treat MM effectively, over time some patients become resistant to currently available standard care regimens and develop relapsed and refractory nature, which remains an incurable cancer. The efficacy of immunotherapies against MM is limited by the complexities of a diverse set of immune cells and interactions between tumor cells and other immunosuppressive cells in the tumor microenvironment of MM. A large proportion of immune cells derived from the innate immunity of the immune system, such as natural killer cells (NK cells), macrophages, and dendritic cells (DCs) present in and around solid tumors serve an alternative immunotherapeutic option, while current strategies mainly focus on the adaptive immunity of the immune system.
CAR T cells undoubtedly remain a critical treatment option for several cancers; however, T cells are not autonomous in their effector functions. In consideration of this, other immune cell populations such as NK cells, macrophages, and dendritic cells from innate immunity, have been identified as potential immunotherapeutic agents. Moreover, these cells are capable of stimulating adaptive immune responses while mounting their own effector responses, such as macrophage via phagocytosis and NK cells through natural cytotoxicity and ADCC process. Recently several studies were ongoing in targeting difficult-to-treat solid cancers via unmodified or genetically modified NK cells and macrophages with or without CAR expression. Moreover, the BM microenvironment harbors a high proportion of NK cells and other immune cells, several studies demonstrated NK cells are more potent to kill MM cells than other immune cells. The present topic will uncover a broad range of innovative innate immune cell-based treatment options against MM.
This Research Topic aims to uncover a broad range of innovative innate immune cell-based treatment options against MM and serves as a forum for new concepts and advances in basic, translational, and clinical trial-based studies involving innate cell immunity against MM treatment. We welcome submissions on broad-ranging ideas, reviews, and results that extend or challenge the established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms and papers that do succeed in reproducing others' results in different contexts.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
CAR T cells undoubtedly remain a critical treatment option for several cancers; however, T cells are not autonomous in their effector functions. In consideration of this, other immune cell populations such as NK cells, macrophages, and dendritic cells from innate immunity, have been identified as potential immunotherapeutic agents. Moreover, these cells are capable of stimulating adaptive immune responses while mounting their own effector responses, such as macrophage via phagocytosis and NK cells through natural cytotoxicity and ADCC process. Recently several studies were ongoing in targeting difficult-to-treat solid cancers via unmodified or genetically modified NK cells and macrophages with or without CAR expression. Moreover, the BM microenvironment harbors a high proportion of NK cells and other immune cells, several studies demonstrated NK cells are more potent to kill MM cells than other immune cells. The present topic will uncover a broad range of innovative innate immune cell-based treatment options against MM.
This Research Topic aims to uncover a broad range of innovative innate immune cell-based treatment options against MM and serves as a forum for new concepts and advances in basic, translational, and clinical trial-based studies involving innate cell immunity against MM treatment. We welcome submissions on broad-ranging ideas, reviews, and results that extend or challenge the established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms and papers that do succeed in reproducing others' results in different contexts.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: immunotherapy, NK cells, CAR NK/ T cells, innate immune cells, CAR Macrophanges, Dendritic cells, Hepatocellular Carcinoma
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
